Świdnik,, Poland
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
This is a prospective, multi center, multinational, non-interventional observational study. All patients will be managed according to the clinical site's normal clinical practice, i.e., the diagnostic and clinical treatment/practice process that a clinician chooses according to their clinical judgement for an SMA patient. Clinical care will not be driven by the protocol. No additional visits or investigations will be performed beyond normal clinical practice. Patients will be followed for 15 years from enrolment or until death, whichever is sooner.
Phase
N/ASpan
1032 weeksSponsor
Novartis PharmaceuticalsToon, Ehime
Recruiting
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Phase
2Span
177 weeksSponsor
Kowa Research Institute, Inc.Toon, Ehime
Recruiting
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Phase
3Span
242 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Phase
3Span
273 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Phase
3Span
214 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase
3Span
1302 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
Toon, Ehime
Recruiting
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Phase
3Span
248 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
All participants undergo an initial induction phase of four cycles, each cycle consisting of pembrolizumab q3w + carboplatin q3w + paclitaxel q3w or nabpaclitaxel weekly. Participants are then randomly assigned to pembrolizumab maintenance vs. pembrolizumab + sac-TMT maintenance.
Phase
3Span
349 weeksSponsor
Merck Sharp & Dohme LLCToon, Ehime
Recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
Phase
2Span
128 weeksSponsor
Mirati Therapeutics Inc.Toon, Ehime
Recruiting